Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chicago, Illinois 60637


This phase I study aims to assess the safety and tolerability of a new drug - CGC-11047 - and to establish what happens to the drug once inside the body. An escalating dose of CGC-11047 will be investigated in this study and the maximum tolerated dose of the drug will be established.

Study summary:

This is an open-label phase I, dose-escalation safety study in subjects with refractory solid tumors. The primary objectives of the study are to assess the safety, tolerability, and pharmacokinetics of CGC-11047. CGC-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. The planned minimum treatment schedule is 2 cycles (8 weeks) of CGC-11047 treatment. Subjects who tolerate treatment may be eligible to receive additional cycles as per investigator's medical judgment. Evaluation of anti-tumor response will be performed every 2 cycles.


Inclusion Criteria: - non-hematological malignancy where standard therapeutic measures do not exist or no longer effective. - ECOG - 0-2. - Life expectancy > 3 months. Exclusion Criteria: - chemotherapy or radiotherapy within 4 weeks prior to entering the study. - previous high-dose chemotherapy with autologous allogeneic hematopoietic stem cell transplantation. - primary brain tumors or active brain metastases - history of significant or symptomatic cardiac arrhythmia, prior myocardial infarction or evidence of a current significant ventricular conduction abnormality



Primary Contact:


Backup Contact:


Location Contact:

Chicago, Illinois 60637
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.